# Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines

> **NCT00644059** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 4902 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** Adjuvanted trivalent inactivated subunit influenza vaccine
- **BIOLOGICAL:** Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine
- **BIOLOGICAL:** Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine

## Key facts

- **NCT ID:** NCT00644059
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2010-04
- **Final completion:** 2010-08
- **Target enrollment:** 4902 (ACTUAL)
- **Last updated:** 2015-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00644059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00644059, "Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00644059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*